Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal MEDICINUS
Gede Dilajaya Robin
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Role of Biologic Agent in The Management of Ankylosing Spondylitis : A Case Report Gede Dilajaya Robin; Gede Kambayana; Robin, Gede Dilajaya
MEDICINUS Vol. 38 No. 10 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/7nbqyy62

Abstract

Background: Ankylosing spondylitis (AS) is a chronic immune-related arthritis primarily affecting the spine, sacroiliac joints, and surrounding tissues. The estimated incidence of AS ranges from 1.30–1.56 million in Europe and from 4.63–4.98 million in Asia. However, data on the current prevalence of AS in Indonesia remains limited. Various treatmentmodalities are available, one of them are biological agents that play a significant role in managing disease progression and preventing complications. Case: A 25-year-old male presented with a four-year history of chronic back pain. Laboratoryresults showed an elevated C-reactive protein (CRP) level of 31.20 mg/dl. Pelvic and thoracolumbar X-ray showed kyphotic deformity, bamboo spine, and dagger spine appearance. The patient was diagnosed with high disease activity ankylosingspondylitis (ASDAS-CRP: 2.9). Initial treatment with nonsteroidal anti-inflammatory drug (NSAID) alone did not result in clinical improvement. Due to the severity of disease activity, combination therapy using NSAID and a tumor necrosis factor (TNF) inhibitor was used, and reported to give satisfactory clinical response. Additionally, patient also underwent corrective spinal surgery due to severe deformity. Conclusion: TNF inhibitors are currently considered as the first-line biological therapy in the management of ankylosing spondylitis, due to their superior efficacy and safety in controlling disease progression compared to other biological agents.
Mortalitas Tuberkulosis Paru di RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar I Gede Ketut Sajinadiyasa; Gede Dilajaya Robin; Putu Andrika
MEDICINUS Vol. 39 No. 4 (2026): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/dw9ejg91

Abstract

Background: Pulmonary tuberculosis (TB) is the second leading cause of death from infectious disease worldwide. According to the World Health Organization (WHO) report in 2022, the global number of deaths due to TB reached 1.3million cases. In Indonesia, the mortality rate due to pulmonary TB in 2021 was 52 cases per 100,000 population. Methods: This is a descriptive study with cross-sectional approach to determine the mortality rate of TB. The subjects were ofpulmonary TB patients recorded at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar, in 2023. The sampling technique used was total sampling. Results: Among the 84 subjects, 33 deaths were recorded. Based on sex, death occurred in 8 (9.5%) female subjects and 25 (29.8%) male subjects. Based on age, death occurred in 8 (9.5%) patients aged ≥60 years and 25 (29.8%) patients aged <60 years. Based on HIV status, death occurred in 20 (23.8%) patients with nonreactive HIV status and 13 (15.5%) patients with reactive HIV status. Based on diabetes status, death occurred in 4 (4.8%) diabetic patients and 29 (34.5%) nondiabetic patients. Based on the type of pulmonary TB, death occurred in 13 (15.5%) patients with clinically diagnosed pulmonary TB and 20 (23.8%) patients with bacteriologically confirmed pulmonary TB. Conclusion: Mortality due to pulmonary TB was more commonly observed among males, individuals under 60 years of age, those withnonreactive HIV status, nondiabetes, and those with bacteriologically confirmed pulmonary TB.
Co-Authors Gede Kambayana I Gede Ketut Sajinadiyasa Putu Andrika Robin, Gede Dilajaya